Indian drugmaker faces LCIA claim over covid vaccine
A Seattle biotech company is bringing an LCIA claim against its Indian former business partner amid a US$950 million dispute over alleged theft of technology used to develop covid-19 vaccines.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.
Subscribe now